Physician profile
Matthew Cort Bell
NPI 1154535953
$88,210.49
in general payments reported to CMS, 2019-2025
30 companies · $36K in 2025
The $36K reported for 2025 was more than what 94% of Pediatric Allergy/Immunology providers received nationally (typical 2025 total: $375).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,186 · 2020: $690 · 2021: $1,248 · 2022: $2,108 · 2023: $2,704 · 2024: $44K · 2025: $36K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $61K · Travel and Lodging: $8,495 · Consulting Fee: $7,480 · Food and Beverage: $6,002 · Education: $83.29.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $60,917.51 |
| Travel and Lodging | $8,495.08 |
| Consulting Fee | $7,480.00 |
| Food and Beverage | $6,001.97 |
| Education | $83.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $71,436.02 | 2019-2025 | Dupixent |
| Genzyme Corporation | $8,779.85 | 2019-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $1,818.84 | 2020-2025 | Takhzyro, Cuvitru, Eohilia |
| Astrazeneca Pharmaceuticals Lp | $1,302.83 | 2019-2024 | Tezspire, Fasenra, Airsupra |
| Glaxosmithkline, LLC. | $1,088.52 | 2019-2024 | Nucala, Trelegy Ellipta, Arexvy |
| Csl Behring | $843.58 | 2019-2024 | Hizentra |
| Genentech USA, INC. | $642.11 | 2019-2025 | Xolair |
| Shire North American Group INC | $270.11 | 2019 | |
| Pharming Healthcare, INC. | $262.36 | 2019-2024 | Ruconest |
| Pfizer INC. | $231.27 | 2019-2024 | |
| Octapharma USA, INC. | $203.25 | 2019-2022 | |
| Amgen INC. | $195.69 | 2021-2024 | Tezspire |
| Biocryst US Sales Co., LLC | $177.25 | 2021-2024 | Orladeyo |
| Grifols USA, LLC | $157.44 | 2019-2023 | Xembify, Prolastin-C Liquid |
| Kaleo, INC. | $131.86 | 2019-2021 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $125.03 | 2021-2024 | |
| Novartis Pharmaceuticals Corporation | $102.44 | 2019-2023 | |
| Abbvie INC. | $96.42 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $92.43 | 2019-2023 | Stiolto Respimat |
| Lilly USA, LLC | $62.06 | 2024-2025 | Ebglyss |
| Merck Sharp & Dohme LLC | $40.09 | 2021-2023 | |
| Bio Products Laboratory USA, INC. | $34.88 | 2022 | |
| Adma Biomanufacturing LLC | $17.07 | 2021 | |
| Ars Pharmaceuticals Operations, INC. | $16.97 | 2025 | Neffy |
| Covis Pharma Gmbh | $16.67 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $14.95 | 2021 | |
| Aimmune Therapeutics, INC. | $13.54 | 2021 | |
| Allergan, INC. | $12.85 | 2020 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $12.35 | 2022 | |
| Biocryst Pharmaceuticals, INC. | $11.76 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Bell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.